Relling MV - Search Results

1

ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy.

Bhojwani D, Pei D, Sandlund JT, Jeha S, Ribeiro RC, Rubnitz JE, Raimondi SC, Shurtleff S, Onciu M, Cheng C, Coustan-Smith E, Bowman WP, Howard SC, Metzger ML, Inaba H, Leung W, Evans WE, Campana D, Relling MV, Pui CH. Bhojwani D, et al. Among authors: relling mv. Leukemia. 2012 Feb;26(2):265-70. doi: 10.1038/leu.2011.227. Epub 2011 Aug 26. Leukemia. 2012. PMID: 21869842 Free PMC article.

2

Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities.

Relling MV, Lin JS, Ayers GD, Evans WE. Relling MV, et al. Clin Pharmacol Ther. 1992 Dec;52(6):643-58. doi: 10.1038/clpt.1992.203. Clin Pharmacol Ther. 1992. PMID: 1458773

3

Disposition of antineoplastic agents in the very young child.

McLeod HL, Relling MV, Crom WR, Silverstein K, Groom S, Rodman JH, Rivera GK, Crist WM, Evans WE. McLeod HL, et al. Among authors: relling mv. Br J Cancer Suppl. 1992 Aug;18:S23-9. Br J Cancer Suppl. 1992. PMID: 1503923 Free PMC article. Review.

4

Variability in teniposide plasma protein binding is correlated with serum albumin concentrations.

Petros WP, Rodman JH, Relling MV, Christensen M, Pui CH, Rivera GK, Evans WE. Petros WP, et al. Among authors: relling mv. Pharmacotherapy. 1992;12(4):273-7. Pharmacotherapy. 1992. PMID: 1518726

5

Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects.

Relling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, Evans WE. Relling MV, et al. Clin Pharmacol Ther. 1991 Sep;50(3):308-13. doi: 10.1038/clpt.1991.141. Clin Pharmacol Ther. 1991. PMID: 1680593

6

Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.

Evans WE, Relling MV. Evans WE, et al. Among authors: relling mv. Pharmacogenetics. 1991 Dec;1(3):143-8. Pharmacogenetics. 1991. PMID: 1688245

7

Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia.

Evans WE, Rodman JH, Relling MV, Petros WP, Stewart CF, Pui CH, Rivera GK. Evans WE, et al. Among authors: relling mv. J Pharmacol Exp Ther. 1992 Jan;260(1):71-7. J Pharmacol Exp Ther. 1992. PMID: 1731053

8

Increased teniposide clearance with concomitant anticonvulsant therapy.

Baker DK, Relling MV, Pui CH, Christensen ML, Evans WE, Rodman JH. Baker DK, et al. Among authors: relling mv. J Clin Oncol. 1992 Feb;10(2):311-5. doi: 10.1200/JCO.1992.10.2.311. J Clin Oncol. 1992. PMID: 1732431

9

Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia.

Evans WE, Rodman J, Relling MV, Crom WR, Rivera GK, Crist WM, Pui CH. Evans WE, et al. Among authors: relling mv. Semin Hematol. 1991 Jul;28(3 Suppl 4):15-21. Semin Hematol. 1991. PMID: 1780747 Review. No abstract available.

10

Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine.

Crom WR, Relling MV, Christensen ML, Rivera GK, Evans WE. Crom WR, et al. Among authors: relling mv. Clin Pharmacol Ther. 1991 Aug;50(2):132-40. doi: 10.1038/clpt.1991.117. Clin Pharmacol Ther. 1991. PMID: 1868674

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

467 results

Search Page

Filters